BE625411A - - Google Patents
Info
- Publication number
- BE625411A BE625411A BE625411DA BE625411A BE 625411 A BE625411 A BE 625411A BE 625411D A BE625411D A BE 625411DA BE 625411 A BE625411 A BE 625411A
- Authority
- BE
- Belgium
- Prior art keywords
- pyridoxine
- solution
- aspartate
- compound
- solvent
- Prior art date
Links
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 26
- 235000008160 pyridoxine Nutrition 0.000 claims description 13
- 239000011677 pyridoxine Substances 0.000 claims description 13
- 229940011671 vitamin b6 Drugs 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- CVTFNNJUXOBPMI-UHFFFAOYSA-N (1,2-dichloro-2-diphenylphosphanylethyl)-diphenylphosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)C(Cl)C(Cl)P(C=1C=CC=CC=1)C1=CC=CC=C1 CVTFNNJUXOBPMI-UHFFFAOYSA-N 0.000 description 1
- GZIJVBKRKQPECN-ARGLLVQISA-N (2r)-2-aminobutanedioic acid;4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound OC(=O)[C@H](N)CC(O)=O.CC1=NC=C(CO)C(CO)=C1O GZIJVBKRKQPECN-ARGLLVQISA-N 0.000 description 1
- CKLJMWTZIZZHCS-YHNMSJHRSA-N (3s)-3-amino-4-deuteriooxy-4-oxobutanoic acid Chemical compound [2H]N[C@H](C(O)=O)CC(O)=O CKLJMWTZIZZHCS-YHNMSJHRSA-N 0.000 description 1
- 241001645425 Ajuga iva Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101150056441 Pctp gene Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE625411A true BE625411A (cg-RX-API-DMAC10.html) |
Family
ID=196658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE625411D BE625411A (cg-RX-API-DMAC10.html) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE625411A (cg-RX-API-DMAC10.html) |
-
0
- BE BE625411D patent/BE625411A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH629479A5 (fr) | Derives de la taurine, medicament contenant ces derives et procede de preparation de ces derives. | |
| DE1922797A1 (de) | Sulfoxyde von 7-Halo-7-desoxylincomycinen und Verfahren zu deren Herstellung | |
| BE625411A (cg-RX-API-DMAC10.html) | ||
| CH561183A5 (cg-RX-API-DMAC10.html) | ||
| DE2641388A1 (de) | Verfahren zur herstellung von derivaten des 3', 4'-dideoxykanamycins b | |
| DE2728097A1 (de) | Sulfoxide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
| CH408900A (fr) | Procédé de préparation de la 3-phénoxy-propylguanidine | |
| CH405264A (fr) | Procédé de préparation des mercapto-succinates de bases azotées | |
| DE259874C (cg-RX-API-DMAC10.html) | ||
| EP0170937B1 (fr) | Sulfate double de desoxyfructosyl-sérotonine et de créatinine, sa préparation et médicament le contenant | |
| BE446318A (cg-RX-API-DMAC10.html) | ||
| DE251935C (cg-RX-API-DMAC10.html) | ||
| DE839937C (de) | Verfahren zur Herstellung eines Benzilsaeurederivates | |
| EP0017525B1 (fr) | Nouveaux dérivés tétrahydroalstoniques, leur préparation et leur application en tant que médicaments | |
| DE270994C (cg-RX-API-DMAC10.html) | ||
| US5292943A (en) | Method for the preparation of low odor 2,3-dimercaptosuccinic acid | |
| BE887922A (fr) | Compositions pharmaceutiques a activites mucolytique, bronchosecretolytique et antibronchospastique | |
| CH314491A (fr) | Procédé de préparation d'acide benzylidène-isonicotoyl-hydrazone-métasulfonique | |
| BE504872A (cg-RX-API-DMAC10.html) | ||
| DE1040560B (de) | Verfahren zur Herstellung von Lysergsaeureamiden | |
| DE1069829B (de) | Verfahren zur Herstellung einer therapeutisch verwendbaren, praktisch neutralen Injektionslösung des Calciumkomplexsalzes der Äthylendiamintetraessigsäure | |
| BE450539A (cg-RX-API-DMAC10.html) | ||
| BE533435A (cg-RX-API-DMAC10.html) | ||
| Ó Cinnéide | Some 2.4. Derivatives of Thiophene | |
| FUJIMOTO | Application de la 2, 6-Lutidine au Medicament. II. Sur la synthese des derives 3, 5-disulfanilamido substitues de lutidone-4 et de pyridone-4 |